SCHEMBL24427520

SCHEMBL24427520

Cc1ncc(-c2ccc3c(N)nn(C)c3c2)[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 9/20 0.45
▸ SCN5A Q14524 1/20 0.42
▸ CYP2A6 P11509 1/20 0.42
▸ AKT1 P31749 1/20 0.38
▸ GSK3B P49841 2/20 0.38
▸ CDK8 P49336 1/20 0.38
▸ CDK19 Q9BWU1 1/20 0.38
▸ KDR P35968 1/20 0.37
▸ CHEK1 O14757 1/20 0.35
▸ AURKA O14965 1/20 0.35
▸ CHEK2 O96017 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ FYN P06241 1/20 0.35
▸ LYN P07948 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ CSNK1D P48730 1/20 0.35
▸ MAPKAPK2 P49137 1/20 0.35
▸ SLC2A1 P11166 1/20 0.33
▸ IRAK4 Q9NWZ3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24427515 0.74 SCN9A (0.41) SCN9ASCN5AAKT1GSK3BCDK8
SCHEMBL24427524 0.74 SCN9A (0.46) SCN9ASCN5AAKT1CDK8CDK19
SCHEMBL24427513 0.73 JAK2 (0.53) KDRAURKAABL1
SCHEMBL21000228 0.72 DDB1 (0.49) SCN9ASCN5AAKT1GSK3BKDR
SCHEMBL24427242 0.72 MAP4K4 (0.49) CYP2A6GSK3BFYN
SCHEMBL24427252 0.71 F9 (0.41) CYP2A6GSK3BCDK8KDRCHEK1
SCHEMBL8233002 0.71 ADORA2A (0.44) SCN9ASCN5AGSK3BKDR
SCHEMBL15443842 0.70 CYP2A6 (0.51) CYP2A6GSK3BIRAK4
SCHEMBL24427567 0.69 CYP2A6 (0.53) CYP2A6GSK3B
SCHEMBL24427241 0.69 CYP2A6 (0.43) SCN9ASCN5ACYP2A6AKT1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) 2022-12-06 — — US disclosed
EP-3998263-A1 TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2022-05-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof TFPI, TFPI2, F11 SCN9A 1993/4885SCN5A 1717/4885CYP2A6 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback